EGFR P772_H773insYNP

CI-VAR-00003401Explore in graph →CIViC 1667

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
EGFR N771delinsGY OR EGFR P772_H773insYNP OR EGFR N771_P772insRH OR EGFR N771_P772insVDN OR EGFR P772delinsHR OR EGFR P772_H773insDNP OR EGFR P772_H773insPHP OR EGFR P772_H773insQ OR EGFR P772_H773insRNP OR EGFR H773delinsNPY OR EGFR H773delinsPNPY	Sunvozertinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID12633 In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC	civic
EGFR P772_H773insYNP	Erlotinib	Predictive	C	Supports Resistance	3	accepted	EID4802 A 79 year old Asian male never smoker with not otherwise specified NSCLC harboring EGFR P772_H773insYNP mutation was given erlotinib as first line treatment, and had progressive disease as best respon… (full text at CIViC) PMID 24353160 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.